RXRX vs. SMMT: Two Biotechs, Two Very Different Bets

Life Science

Insiders Sell Nearly $900,000 in Stock as Monterosa Medical Faces Key Clinical Data Test

Life Science

AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying?

Life Science

CVS Health Launches One-Stop Service Plan for GLP-1 Weight Loss Drugs

Life Science

Kymera Jumps on Rapid Eczema Trial Enrollment; Takeover Talk Swirls

Life Science

Innovative Pipeline Supports Long-Term Value, Moderna Still Has Upside After Doubling in Price

Life Science

Merck KGaA’s $11.3 Billion Bio-Techne Buy Bolsters CGT Ambitions in Biggest Deal Since 2014

Life Science

Impressive Clinical Trial Data Drives Intellia Therapeutics Up 70% This Year

Life Science

After a 57% Rally, Is UnitedHealth Group Still a Buy?

Financial Service, Life Science

How Should Investors Weigh the Trade-Off Between Amgen and Iovance?

Life Science

2x Valuation Gap: BIO vs. CRL — Who’s Wrong?

Life Science

Mid-Cap Biotech Viking Therapeutics Could Emerge as a Potential Challenger to Eli Lilly and Novo Nordisk

Life Science

Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee

Life Science

Grail Missed Its Endpoint, But Investors May Have Missed the Real Story

Life Science

AI Rewrites Drug Discovery: Eli Lilly and Twist Bioscience Chart Two Distinct Industrialization Paths

Life Science, Technology